Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs GLUE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GLUE Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

GLUE Overall Winner 6-Pillar Tally: RGNX 3 – 3 GLUE Matrix Metrics: RGNX 4 – 6 GLUE

As of Nov 16, 2026, Monte Rosa Therapeutics, Inc. (GLUE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas GLUE carries 44.2/100 (HOLD) at $9.11 (10.0x Forward P/E, -214.5% operating margin).

  • Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. GLUE 44.2/100 HOLD), GLUE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-214.5% vs. -120.4% operating margin) and revenue trajectory (+325.8% vs. -69.2% YoY).
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs GLUE
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
GLUE NASDAQ Head-to-Head Winner
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.11
-2.77% 1D
Market Cap $795.5M
TTM Revenue $70M
Forward P/E 10.0x
Beta / 30D Vol 0.94β · 53% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $10.50 · SMA50: $11.21

6-Pillar Scorecard Institutional Category Breakdown (RGNX 3 – 3 GLUE)

Columns: Metric · RGNX · GLUE
1. Valuation Multiples GLUE
Forward P/E N/M 10.0x
Trailing P/E N/M 10.0x
PEG Ratio 0.26x N/M
EV / Revenue 3.1x 11.2x
2. Growth & Scale GLUE
Revenue Growth (YoY) -69.2% +325.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M $70M
Market Cap $500.9M $795.5M
3. Profitability & Quality RGNX
Gross Margin -64.5% -92.2%
Operating Margin -120.4% -214.5%
Net Profit Margin -113.9% -186.2%
Return on Equity (ROE) -113.2% -35.3%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$174M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $8.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GLUE
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 349.6% (52nd %ile) 100.8% (16th %ile)
Put/Call OI Skew N/A 6.27x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (4) vs GLUE (6)
Institutional Metric RGNX GLUE Criterion Row Edge
Market Capitalization
Scale
$500.9M $795.5M Larger Scale GLUE
Trailing P/E Ratio
Valuation
N/M 10.0x Lower Multiple GLUE
Forward P/E Ratio
Valuation
N/M 10.0x Lower Multiple GLUE
Revenue Growth (YoY)
Growth
-69.2% +325.8% Higher Growth GLUE
Operating Margin (TTM)
Profitability
-120.4% -214.5% Higher Margin RGNX
Net Profit Margin
Profitability
-113.9% -186.2% Higher Margin RGNX
Return on Equity (ROE)
Capital Efficiency
-113.2% -35.3% Higher ROE GLUE
52-Week Range Position
Momentum
19% ($5–$16) 1% ($9–$26) Stronger Trend RGNX
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 0.94β · 53% Vol Lower Realized Risk GLUE
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$154M $70M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% -92.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · 11.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$174M ($8.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +14.34 pp
RGNX: +7.87% · GLUE: -6.47%
3M Horizon RGNX +6.87 pp
RGNX: -32.52% · GLUE: -39.39%
6M Horizon RGNX +81.63 pp
RGNX: +32.21% · GLUE: -49.42%
1Y Horizon RGNX +0.56 pp
RGNX: -35.82% · GLUE: -36.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue GLUE Revenue RGNX Op. Margin GLUE Op. Margin Margin Leader
FY2018 $220M N/A 40.3% N/A RGNX
FY2019 $40M N/A -422.9% N/A RGNX
FY2020 $150M N/A -77.1% N/A RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M N/A -297.1% N/A RGNX
FY2024 $80M $80M -280.0% -107.3% GLUE
FY2025 $170M $120M -94.6% -43.8% GLUE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GLUE BREAKDOWN
85d in phase · OBV DISTRIBUTION
Current IV 100.8%
IV Percentile 16th %ile
Put/Call OI Skew 6.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
GLUE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $795.5M market capitalization and -214.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs GLUE Key Questions & Quantitative Answers

As of Nov 16, 2026, Monte Rosa Therapeutics, Inc. (GLUE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas GLUE carries 44.2/100 (HOLD) at $9.11 (10.0x Forward P/E, -214.5% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. GLUE 44.2/100 HOLD), GLUE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-214.5% vs. -120.4% operating margin) and revenue trajectory (+325.8% vs. -69.2% YoY). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile GLUE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLUE leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with GLUE at +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while GLUE shifted +50.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GLUE.

GLUE screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus GLUE (-35.3% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.